Research Article

Young and Especially Senescent Endothelial Microvesicles Produce NADPH: The Fuel for Their Antioxidant Machinery

Guillermo Bodega 1, Matilde Alique, 2 Lourdes Bohórquez, 2 Miriam Morán, 2 Luis Magro, 2 Lilian Puebla, 2 Sergio Ciordia, 3 María C. Mena, 3 Elvira Arza, 4 and Manuel R. Ramírez 2

1Departamento de Biomedicina y Biotecnología, Universidad de Alcalá, Alcalá de Henares, 28805 Madrid, Spain
2Departamento de Biología de Sistemas, Universidad de Alcalá, Alcalá de Henares, 28805 Madrid, Spain
3Proteomics Facility, Centro Nacional de Biotecnología, CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
4Unidad Técnica de Microscopía, CNIC, C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain

Correspondence should be addressed to Guillermo Bodega; guillermo.bodega@uah.es

Received 13 December 2017; Revised 14 February 2018; Accepted 25 February 2018; Published 5 April 2018

1. Introduction

Extracellular vesicles are subcellular structures produced by many different cells and located in the extracellular compartment. There are diverse types of extracellular vesicles depending on their biogenesis, content, function, and/or biophysical properties [1, 2]. The most common classification includes three types: microvesicles (MVs) (also termed microparticles or ectosomes), exosomes, and apoptotic bodies [3]. MVs are released from the cell by the budding of the plasma membrane and represent not only a heterogeneous structural population, since their size usually ranges from 0.15 to 1 μm or more, but also a heterogeneous functional group. They are present in all the body fluids: urine, saliva, bile, amniotic liquid, synovial, cerebrospinal, and seminal fluids as well as blood. Plasma MVs are of diverse cellular origin; they can arise from endothelial cells, erythrocytes, platelets, and leucocytes [4]. Blood MVs have been involved in the regular maintenance of endothelial cells [5] and other physiological functions such as coagulation, reticulocyte maturation, and angiogenesis [3] as well as mediators of endothelial dysfunction [6]. They have also been used as therapeutic tools in cardiovascular disease [7].

Reactive oxygen species (ROS) are produced as a consequence of cell metabolism, although the cells contain different mechanisms to eliminate them. In fact, the oxidative stress...
caused by an increase of ROS can be considered as an imbalance between ROS production and elimination. Although ROS have physiological roles in the regulation of vascular cell function [8], vascular formation, and development [9], this imbalance has been associated with aging and senescence [10-14] as well as other pathological conditions of the cardiovascular system [15-17], more specifically, with endothelial cell dysfunction [18-24].

NADPH is, obviously, closely related to NADH, another molecule with a reducing activity. Both may act as common mediators in different biological processes. Hence, it is common to find the term NAD(P)H, indicating that both molecules may be involved. Nevertheless, NAD$^+$ is mainly involved in catabolic reactions and mitochondrial functions, whereas NADP$^+$ is involved in cellular antioxidant systems and anabolic reactions [25]. In fact, NADPH is considered the sole source of reducing power of antioxidant systems [26]. This is the reason why NADPH is considered the "fuel" of the antioxidant machinery. We have recently demonstrated that endothelium-derived MVs (eMVs) have a well-developed and functional enzymatic team to eliminate ROS which, moreover, increases in senescence [27]. Apparently, if eMVs can eliminate ROS, they should (a) contain large amounts of NADPH, (b) obtain it from the plasma, or (c) be able to synthesize it. Thus, the aim of this work was to elucidate these questions. In addition, given the differences observed in our previous study, where senescent eMVs showed a higher capacity of ROS elimination than young eMVs, we have also analyzed the capacity of eMVs obtained from both young and senescent endothelial cells to produce NADPH.

2. Material and Methods

2.1. HUVEC Culture. Cryopreserved human umbilical vein endothelial cells (HUVECs) (ATCC Cat number PCS-100-010) were cultured in endothelial growth medium (Lonza) supplemented with 10% heat-inactivated foetal bovine serum (Sigma-Aldrich). Cultures were maintained at 37 °C in a 5% CO$_2$ atmosphere at 95% humidity. The HUVECs were serially passaged (the replicative senescence model). Cells passed <8 times (population doubling (PD) <20; with PD calculated as $[\ln(\text{number of cells harvested}) - \ln(\text{number of cells seeded})]/\ln(2)$) were regarded as young endothelial cells, while those passed 27–35 times (PD >96) were regarded as senescent [28]. The proliferation rate of the latter cells is remarkably reduced, and more than 70% are positive for β-galactosidase. Prior to use, HUVEC extracts from cells passaged 4–8 (young pool) and from cells passaged 27–35 (senescent pool) were mixed (performed in quadruplicate).

2.2. Isolation and Characterization of Young and Senescent eMV. Young and senescent HUVEC-derived MVs were isolated from their culture medium. Briefly, samples were centrifuged using serial centrifugations (15 min at 3000 rpm, 30 min at 14,000 rpm), and pellets were frozen and stored at −20°C until use. Prior to use, MVs from cells passaged 4–8 (young pool) and from cells passaged 27–35 (senescent pool) were mixed (performed in quadruplicate).

MVVs from a medium containing young and senescent HUVEC cells were characterized in terms of size using a Beckman Coulter Cytometers FC 500 flow cytometer running CXP software. MVs were considered to be those events gated with a size between 0.5–1.5 μm; this gate was established from the side scatter versus forward scatter dot plot produced in a standardization experiment using the SPHERO™ Flow Cytometry Nano Fluorescent Size Standard Kit (Spherotech). The latter has size-calibrated fluorescent beads ranging from 0.1–1.9 μm in diameter. Events below 0.2 μm were excluded in order to adequately distinguish true events from the background; events >1.9 μm were excluded to prevent possible confusion with apoptotic bodies. The absolute number of MVs (events) per μL was determined using Flow Count calibrator beads (Beckman Coulter) according to the manufacturer’s recommendations and employing CXP software: (MVs counted × standard beads/L)/(standard beads counted). Data were recorded as the mean of three independent measurements of the same sample. The same number of senescent and young MVs was used in comparative analyses.

2.3. Western Blotting. The total protein content of extracts from young and senescent eMVs (performed using CytoBuffer Protein Extraction Reagent lysis buffer (Millipore), which contains a protease and a phosphatase inhibitor cocktail (Roche), was quantified using a BCA Protein Assay Kit (Pierce), employing BSA as the standard. Briefly, equal amounts of protein (25 μg protein/lane) were diluted with a reducing sample buffer and separated by 4–20% MiniPROTEAN® TGX™ Precast Protein Gels under reducing conditions. These proteins were then transferred onto nitrocellulose membranes (BioRad), blocked with TBS containing 0.1% Tween 20 and 5% dry nonfat milk for 1 h at room temperature, and incubated in the same buffer with different primary antibodies (anti-6PGL, Santa Cruz, sc-398833, dilution 1:500, 28 kDa; anti-GK, Santa Cruz, sc-395355, dilution 1:250, 61 kDa; anti-PSH, Santa Cruz, sc-271421, dilution 1:250, 25 kDa). After washing with TBST, the membranes were incubated with Novex horseradish peroxidase-conjugated secondary antibodies followed by 2 additional washing steps with TBST. Bands were visualized with Luminata Crescendo Western HRP substrate (Millipore). Ponceau red (Sigma) staining was used as a loading control. Bands were quantified using Image J software (NIH) and normalized to Ponceau red.

2.4. Mass Spectrometry for NADPH Analysis. The presence of NAD$^+$ and NADPH in eMVs was analyzed using a HPLC system Agilent 1100 coupled in-line to a TSQ Quantum triple quadrupole mass spectrometer (Thermo Scientific) equipped with an ESI source. Samples were prepared according to the "hot water/buffer extraction" protocol from Ortmayr [29]. Briefly, eMVs (50 × 10$^7$) were added to 250 μL of 5 mM ammonium acetate buffer at pH 8.0. The supernatant was collected after sample incubation for 3 min at 85°C, cooling on dry ice, and centrifugation for 10 min at 4000×g. Equipment settings were also obtained from Ortmayr [29] (see Table 1). Mass spectra were recorded in negative mode for NADP$^+$ and NADPH. The column used was ACE Excel
Table 1: Compound optimization table in MS/MS mode.

| Molecular formula in MS | NADP⁺ | NADPH |
|------------------------|-------|-------|
| C₂₁H₂₇N₇O₁₇P₃       | 742 m/z | 744 m/z |
| Parent mass            | 619.96 m/z/17 v 426.16 m/z/35 v |
| Product ion (m/z)/collision energy | 407.89 m/z/34 v 407.96 m/z/36 v |
|                        | 272.82 m/z/38 v 396.96 m/z/32 v |

3 C18 -PFP 150 mm × 3.0 mm + 3 μm. Mass spectra of the column eluates were recorded in MS/MS mode using methanol and H₂O, adding 5 mM ammonium acetate. Nitrogen was used as the ion source gas. The sheath gas pressure was set at 40 (arbitrary units), the auxiliary gas pressure was set at 2 (arbitrary units), and the spray voltage was set at 3000 V. The capillary temperature was set at 350°C. Argon was used as the collision gas for collision-induced dissociation at a pressure of 1.5 mTorr (Q2). Data were acquired using Xcalibur Control Software.

2.5. Proteomic Analysis. Proteomic analysis involved in-gel protein digestion followed by HPLC and mass spectrometry (MS). In order to obtain sufficiently large samples, the four HUVEC “young pool” extracts (see Section 2.2) were mixed, as were the four HUVEC “senescent pool” extracts, and the corresponding pools for the MVs. These four samples were dissolved in lysis buffer (8 M urea, 2 M thiourea, 5% CHAPS, 2 mM TCEP-HCl, and protease inhibitors). MVs were lysed by ultrasonication (10 strokes, low amplitude) on ice. The lysates were then centrifuged at 20,000 x g for 10 min at 4°C, and the supernatant containing the solubilized proteins was used for LC-MS/MS experiments. Total protein concentration was determined using the Pierce 660 nm protein assay (Thermo). An aliquot of each sample was diluted with loading sample buffer and then loaded onto 1.2 cm wide wells of a conventional SDS-PAGE gel (1 mm thick, 4% stacking gel, and 12% resolving gel). The run was stopped as soon as the front entered 1 cm into the resolving gel, so that the whole proteome became concentrated at the stacking/resolving gel interface. The separated protein bands were visualized by Coomassie staining, excised, cut into cubes (cross section 1 mm²), deposited in 96-well plates, and processed automatically in a Proteineer DP (Bruker Daltonics). The digestion protocol used was based on Shevchenko et al. [30] with minor variations: gel plugs were washed firstly with 50 mM ammonium bicarbonate and secondly with acetonitriile prior to reduction with 10 mM dithiothreitol in 25 mM ammonium bicarbonate solution; alkylation was performed with 55 mM iodoacetic acid in 50 mM ammonium bicarbonate solution. The gel pieces were then rinsed, firstly with 50 mM ammonium bicarbonate and secondly with acetonitriile, and subsequently dried under a stream of nitrogen. Proteomics grade trypsin (Sigma-Aldrich) at a final concentration of 16 ng/μL in 25% acetonitriile/50 mM ammonium bicarbonate solution was added and digestion allowed to proceed at 37°C for 4 h. The reaction was stopped by adding 50% acetonitriile/0.5% trifluoroacetic acid for peptide extraction. The tryptic-eluted peptides were dried by speed-vacuum centrifugation and then desalted on StageTip C18 Pipette tips (Thermo Scientific) until analysis by mass spectrometry.

A 1 μg aliquot of each sample was subjected to 1D-nano LC ESI-MSMS analysis using an Eksigent Technologies nanoLC Ultra 1D plus nanoliquid chromatography system coupled to a high-speed Triple TOF 5600 mass spectrometer (SCIEX) with a Nanospray III source. The analytical column used was a silica-based reversed phase Acquity UPLC M-Class Peptide BEH C18 Column (75 μm × 150 mm, 1.7 μm particle size, and 130 Å pore size) (Waters). The trap column was a C18 Acclaim PepMap™ 100 (Thermo Scientific) (100 μm × 2 cm, 5 μm particle diameter, and 100 Å pore size), switched on-line with the analytical column. The loading pump delivered a solution of 0.1% formic acid in water at 2 μL/min. The nanopump provided a flow-rate of 250 nL/min and was operated under gradient elution conditions. Peptides were separated using a 2–90% mobile phase B gradient (mobile phase A: 2% acetonitrile, 0.1% formic acid; mobile phase B: 100% acetonitrile, 0.1% formic acid) for 250 min. The injection volume was 5 μL.

Data acquisition was performed with a Triple TOF 5600 System (SCIEX) (ionspray voltage floating 2300 V, curtain gas 35 psi, interface heater temperature 150°C, ion source gas 1 25 psi, and declustering potential 100 V). All data were acquired using information-dependent acquisition (IDA) mode with Analyst® TF 1.7 software (SCIEX). The following IDA parameters were chosen: a 0.25 s MS survey scan in the mass range 350–1250 Da, followed by 35 MS/MS scans of 100 ms in the mass range 100–1800 (total cycle time: 4 s). Switching criteria were set to ions greater than a mass to charge ratio (m/z) of 350 and smaller than 1250, with a charge state of 2–5 and an abundance threshold of more than 90 counts/s (cps). Former target ions were excluded for 15 s. The IDA rolling collision energy (CE) parameters script was used for automatically controlling the CE.

MS and MS/MS data obtained from individual samples were processed using Analyst TF 1.7 software. Raw data file conversion tools were used to generate mgf files which were then compared (using Mascot Server v.2.5.1 software; Matrix Science) to those in the UniProt Homo sapiens protein database. The latter contains 40,530 coding genes and their corresponding reversed entries. The search parameters were set as follows: carbamidomethyl (C) as the fixed modification and acetyl (protein N-term) and oxidation (M) as the variable modifications. Peptide mass tolerance was set to 25 ppm and 0.05 Da for fragment mass. Two missed cleavages were allowed. False discovery rates (≤1% at the spectral level) for peptide identification were calculated manually.

2.6. Functional Experiments. Two functional experiments were carried out in order to (1) test the ability of MVs to use blood metabolites to feed the NAD(P)H synthesis machinery, and (2) visually demonstrate that these metabolites induce NAD(P)H formation.

In the first experiment, five different blood metabolites were tested separately on young and senescent eMVs: lactate, pyruvate, glucose, branched-chain amino acids (BCAA; Val, Leu, Ileu), and glycerol. The concentration used was higher
The pentose phosphate pathway

3.1. Proteomic Analysis.

To visualize NAD(P)H synthesis, the eMVs (young and senescent) were incubated for 10 min with the blood metabolites previously described. Subsequently, 10 μL of each sample including 40,000 eMVs was dropped into the center of a small water-repellent circle made on a slide with a PAP pen. The drop and the circle were wrapped up with a coverslip and observed in a Zeiss LSM 780 multiphoton confocal microscope with a Mai-Tai DS (690–1040 nm tunable) laser. The excitation wavelength was 735 nm, more than twice that of NAD(P)H (340 nm), and the laser intensity was set at 5.5%. The detection range was 396–502 nm.

2.7. Statistical Analysis. Data were analyzed using R software. The two-tailed Student t-test was used to analyze differences in Western blotting results. Data of our first functional experiment (ability of MVs to use blood metabolites to feed the NAD(P)H synthesis machinery) were analyzed as follows. Kruskal-Wallis test (with post hoc Dunn’s test) was performed for the comparison of the effect of metabolites in young eMVs and senescent eMVs. Mann-Whitney–Wilcoxon rank-sum test was used to compare the effect of every molecule between young and senescent: glucose in young versus glucose in senescent and so on. Significance was set at p < 0.05.

3. Results

This section has been organized in three parts: (1) proteomic analysis, where we describe the biochemical pathways in eMVs which are directed at synthesizing NADPH; (2) the presence of NADP⁺ in eMVs; and (3) functional analysis, to demonstrate whether or not eMVs can synthesize NAD(P)H after activation of the pathways previously described. In the text that follows, the enzymes are named using the acronyms included in Table 2, the generic name (GN), and the metabolites with the acronyms included in Figure 1.

3.1. Proteomic Analysis. The pentose phosphate pathway (PPP) is the main biochemical route to synthesize NADPH. Hence, our first objective was to search for the presence of enzymes that participate in this pathway using mass spectrometry (MS) analysis of young and senescent eMVs. The majority of PPP enzymes were detected in this MS analysis, as shown in Table 2, except for 6PGL, G6K, and PSPH, which were detected by Western blot (WB) analysis (Figure 2).

We next carried out a more detailed analysis of the enzymes detected in our MS results in order to connect the PPP with other biochemical routes. Table 2 includes the enzymes of the PPP and those of related metabolic routes proposed according to our proteomic analysis. To clarify these routes, a diagram of all the metabolic pathways proposed is included in Figure 1.

The organization of the different enzymes found in our proteomic analysis led us not only to establish the hypothetical biochemical routes that may be operative in the eMVs but also to point out the metabolites that feed these biochemical routes (Figure 1). All in all, it seems that both young and especially senescent eMVs have a very well-developed enzymatic organization designed to optimize NADPH production, and this is mainly due to the bidirectionality of most of these enzymatic activities. Besides the glycolytic pathways, which use glucose, lactate, and pyruvate, it is very important to point out the possibility that BCAA and glyceraldehyde can also be used to direct metabolites to the PPP. Mitochondria are also involved in this strategic metabolic organization: they can act as an NADPH biosynthetic organelle (note the high content of GLUD1 (number 22)) and supply AKG to the serine and 3PHP pathway. Enzymes involved in serine and glyceraldehyde metabolism are also included in these biochemical pathways using 3PHP and 3PG as metabolic intermediates.

One of the most interesting results was the higher content of most of these enzymes in senescent eMVs when compared with young eMVs; in fact, their enzymatic machinery seems to be designed to direct metabolites to the PPP or to obtain NADPH from new routes not included in young eMVs. The bold numbers in Table 2 indicate an increase >25% when young and senescent eMVs were compared. A route especially used in senescent eMVs is the serine and PHP pathway, as suggested by the high content of the enzymes involved (numbers from 23 to 27) in senescent eMVs. The use of glutamine to form F6P using GFPT2 (number 28) is also especially elevated in senescent eMVs. Moreover, at the bottom of Table 2, we have included five enzymes that synthesize NADPH but are not included in Figure 1. Note that IDH1 and IDH2 are decreased in senescent eMVs, whereas the last three enzymes are increased.

3.2. Functional Analysis. We carried out two types of functional analysis; one to test the capacity of the proposed blood metabolites to feed the enzymatic machinery involved in reducing power synthesis and the other one to visualize this reducing power in eMVs. Unfortunately, NADH and NADPH are closely related molecules whose absorption and emission spectra are almost equal and, thereby, it has been impossible for us to separate NADH from NADPH in these functional analyses.

In order to study the effect of blood metabolites on NAD(P)H synthesis, eMVs were incubated 30 min with
the proposed metabolites (lactate, pyruvate, glucose, glycerol, and BCAA). These metabolites were incubated separately at a concentration that doubled the maximal value indicated in Figure 1. The absorbance ratio 260 nm/340 nm is a measure of the relative proportion of NAD(P)+/NAD(P)H. In young eMVs, lactate and pyruvate diminished significantly this ratio, which indicates that both metabolites induced the formation of NAD(P)H. However, in senescent eMVs, all the metabolites tested induced a decrease in this ratio, glycerol and pyruvate being statistically significant. Statistically significant differences were also observed for glucose, glycerol, and BCAA when the effect of metabolites was compared in young and senescent eMVs (Figure 3).

An experiment using multiphoton confocal microscopy was performed to visualize the production of NAD(P)H by eMVs after incubation with the previously used metabolites. In order to detect only the reduced forms, eMVs were excited at 340 nm (670 nm in the multiphoton confocal microscope), and emission was detected at 460 nm. Only after incubation with the proposed blood metabolites could eMVs be clearly visualized, demonstrating that eMVs have the capacity to synthesize reducing power (NAD(P)H) (Figure 4), although not all vesicles were able to produce fluorescence. Only lactate and pyruvate induced fluorescence in young eMVs, and senescent eMVs seemed to be more efficient in producing fluorescence.

3.3. NADP⁺ and NADPH in eMVs. An MS analysis was carried out to accurately detect the presence of NADP⁺ and NADPH in eMVs. As can be seen in Figure 5, the presence of both cofactors was demonstrated in eMVs, although the content of NADP⁺ was greater than that of the reduced form. Differences in the NADP⁺/NADPH ratio were not observed either following incubation with the blood metabolites or between young and senescent eMVs.

4. Discussion

In a recent work, we demonstrated the existence of a functional machinery for ROS detoxification in HUVEC eMVs [27]; now, our present study demonstrates that these HUVEC eMVs, especially those derived from senescent cells, can synthesize NAD(P)H, the fuel that feeds the antioxidant machinery, used as precursors of different blood plasma metabolites. The combination of both results indicates that eMVs are subcellular structures with an autonomous capacity for ROS scavenging, as had been suggested by Soleti et al. [31]; eMV protection against oxidative stress regulating eNOS/Akt signaling has also been recently demonstrated [32]. Figure 6 shows a schematic drawing that represents our past and present results on the role of eMVs as ROS scavengers.

The presence of some antioxidant enzymes in plasma MVs [33–35], in endothelial-derived MVs [36], and in...
Table 2: Proteomic analysis of young and senescent eMVs. PS: protein score; PSM: peptide-spectrum match; NP: number of peptides (MS/MS scores are sums for the validated peptides assigned to each protein); C: coverage. PS, PSM, and NP are usually considered quantitative variables in the proteomic analysis. Bold numbers in the "senescent columns" indicate a 25% increase in senescent eMVs; italic numbers in "young columns" indicate a 25% reduction in senescent eMVs. The 5 proteins at the bottom of the table are the enzymes that synthesize NADPH. UniProt: UniProt code; GN: generic name.

| Enzymes | UniProt | GN | Young eMVs | Senescent eMVs |
|---------|---------|----|------------|---------------|
|         | PS | PSM | NP | % | PS | PSM | NP | % | |
| 1 | L-Lactate dehydrogenase B chain | P07195 | LDHB | 644 | 17 | 10 | 32 | 837 | 18 | 12 | 33.8 |
| 2 | L-Lactate dehydrogenase A chain | P00338 | LDHA | 458 | 14 | 7 | 25.6 | 1023 | 26 | 15 | 53.6 |
| 3 | L-Lactate dehydrogenase A-like 6A | Q6ZMR3 | LDHAL6A | 104 | 2 | 1 | 6.3 | 105 | 2 | 1 | 6.3 |
| 4 | Pyruvate kinase | P14618 | PKM | 1425 | 40 | 24 | 56.9 | 1675 | 44 | 24 | 60.8 |
| 5 | Alpha-enolase | P06733 | ENO1 | 810 | 14 | 10 | 49.8 | 1376 | 31 | 18 | 60.4 |
| 6 | Fructose-bisphosphate aldolase A | P04075 | ALDOA | 565 | 12 | 9 | 44.2 | 1202 | 29 | 19 | 59.9 |
| 7 | Hexokinase-1 | P19367 | HK1 | 265 | 5 | 5 | 16.4 | 262 | 7 | 5 | 9.6 |
| 8 | Phosphoglycerate mutase 1 | P18669 | PGAM1 | 197 | 6 | 3 | 33.5 | 352 | 11 | 6 | 44.5 |
| 9 | Glucose-6-phosphate isomerase | P00558 | PKG1 | 524 | 12 | 7 | 46.5 | 519 | 12 | 8 | 45.6 |
| 10 | Glucose-6-phosphate 1-dehydrogenase | P11413 | G6PD | 45 | 1 | 1 | 11.8 |
| 11 | 6-Phosphogluconolactonase | O95336 | 6PGL | Western blot |
| 12 | 6-Phosphogluconate dehydrogenase, decarboxylating | P52209 | PGD | 162 | 3 | 3 | 22.2 | 160 | 3 | 3 | 24.2 |
| 13 | Transketolase | P29401 | TKT | 238 | 7 | 4 | 14.4 | 185 | 6 | 4 | 19.3 |
| 14 | Hexokinase-1 | P19367 | HK1 | 265 | 5 | 5 | 16.4 | 262 | 7 | 5 | 9.6 |
| 15 | Glycerol kinase | P32189 | GK | Western blot |
| 16 | Glyceraldehyde-3-phosphate dehydrogenase | P04406 | GAPDH | 1645 | 50 | 23 | 75.5 | 1939 | 65 | 27 | 72.2 |
| 17 | Fructose-bisphosphate aldolase C | P09972 | ALDOC | 310 | 5 | 4 | 13.8 | 474 | 9 | 7 | 25.3 |
| 18 | Fructose-2,6-bisphosphatase | Q9NQ88 | TIGAR | 46 | 1 | 1 | 6.7 |
| 19 | Fructose-2,6-bisphosphatase | O95336 | 6PGL | Western blot |
| 20 | Fructose-2,6-bisphosphatase | P08559 | PDHA1 | 5 | 3 | 5 | 13.8 | 80 | 2 | 1 | 5.4 |
| 21 | Fructose-2,6-bisphosphatase | P11177 | PDHB | 114 | 2 | 2 | 17.3 | 38 | 1 | 1 | 9.7 |
| 22 | Fructose-2,6-bisphosphatase | O15382 | BCAT2 | 94 | 1 | 1 | 6.4 |
| 23 | Fructose-2,6-bisphosphatase | P00337 | GLUD1 | 329.0 | 6.0 | 5.0 | 38.7 | 637.0 | 17.0 | 11.0 | 35.5 |
| 24 | Fructose-2,6-bisphosphatase | P48735 | MDH1 | 99 | 3 | 1 | 10.8 | 176 | 5 | 3 | 17.7 |
| 25 | Fructose-2,6-bisphosphatase | O43175 | PHGDH | 80 | 2 | 1 | 5.1 | 391 | 8 | 6 | 23.3 |
| 26 | Fructose-2,6-bisphosphatase | Q9Y617 | PSAT1 | 47 | 1 | 1 | 5.4 |
| 27 | Fructose-2,6-bisphosphatase | P78330 | Western blot |
| 28 | Fructose-2,6-bisphosphatase | P98559 | PDHA1 | 5 | 3 | 5 | 13.8 | 80 | 2 | 1 | 5.4 |
| 29 | Fructose-2,6-bisphosphatase | P11177 | PDHB | 114 | 2 | 2 | 17.3 | 38 | 1 | 1 | 9.7 |
| 30 | Fructose-2,6-bisphosphatase | O15382 | BCAT2 | 94 | 1 | 1 | 6.4 |

Other NAD(P)H-related enzymes

- Isocitrate dehydrogenase (NADP) cytoplasmic
  - O75874 | IDH1 | 41 | 1 | 1 | 2.7 |
- Isocitrate dehydrogenase (NADP), mitochondrial
  - P48735 | IDH2 | 254.0 | 6.0 | 5.0 | 38.7 | 133.0 | 3.0 | 3.0 | 30.8 |
- Flavin reductase (NADPH) Alpha-aminoacidic semialdehyde
  - P30043 | BLVRB | 37 | 1 | 1 | 12.1 |
- Alpha-aminoacidic semialdehyde dehydrogenase
  - P49419 | ALDH7A1 | 111 | 2 | 2 | 11.9 | 207 | 5 | 4 | 16.5 |
- NAD(P)H dehydrogenase (quinone)
  - P15559 | NQO1 | 39 | 1 | 1 | 6.6 |
HUVEC-derived MVs [31] had been already demonstrated. However, in our previous work [27], we demonstrated that HUVECs had a complete antioxidant machinery and that their MVs included a specific group of functional enzymes mainly involved in $\text{O}_2^-$ and H$_2$O$_2$ detoxification. Moreover, to date, the possibility of NADPH synthesis in MVs has not been considered in the literature. As far as we know, this is the first time that the capacity of NADPH synthesis is ascribed to eMVs, although the existence of some PPP enzymes has been demonstrated in exosomes [37], and some enzymes included in Table 2 have also been found in different proteomic studies: numbers 1, 5, 6, 7, and 18 and IDH2 [36]; numbers 5, 6, and 7 [33]; numbers 6 and 7 and ALDH [35]; and numbers 10, 20, and 27 and ALDH [34]. The synthesis of NADPH in eMVs seems logical; it makes no sense to contain an antioxidant machinery without the capacity of synthesizing the molecule that feeds it.

NADPH is considered the essential reductant for antioxidant systems. Unfortunately, its absorption and emission spectra are very similar to that of NADH. The appearance of FLIM [38, 39] and MS [29] methods, however, has made it possible to study these metabolites separately. FLIM permits the monitoring of MVs, but the use of MS is ideal for quantitative comparative studies of oxidized (NADP$^+$) and reduced (NADPH) forms. eMVs have an important handicap: it is difficult and very expensive to obtain large amounts of eMVs using HUVEC. This handicap has made our attempts to determine the NADP$^+$/NADPH ratio using the standard commercial kits for NADPH analysis impossible. This problem can be resolved using FLIM, but this technique is very expensive and not usually available in most laboratories. While it is true that MS does not require big amounts of sample, even so, it is complicated to obtain enough eMVs for MS, and this problem gets worse in endothelial senescent cells because it is not easy to reach PD $>$ 96.

To clarify the plot, only statistical significance of the Mann–Whitney–Wilcoxon rank-sum test is included. $^*p < 0.05$, $^{**}p < 0.01$. In the Kruskall-Wallis test for young eMVs, significant differences were observed in control versus lactate and pyruvate ($p < 0.05$) and between glucose versus lactate ($p < 0.01$). Significant differences were also observed for senescent eMVs in control versus glycerol and pyruvate ($p < 0.05$) and between glycerol versus glucose and lactate ($p < 0.01$).

Figure 2: Western blot analysis of 6PGL, GK, and PSPH and the corresponding normalized analysis. A representative pool is included in the figure: young (Y) and senescent (S). THP-1 cells were used as a positive control (not shown). Bands were located at the expected molecular weight of 6PGL (28 kDa), GK (61 kDa), and PSPH (25 kDa). Protein data for the eMVs was normalized against the intensity of Ponceau red staining. Bars represent mean ± SD ($n = 4$ pools). $^{***}p < 0.001$.

Figure 3: Effect of incubating eMVs with different blood plasma metabolites on the ratio of absorbance at 260 nm and 340 nm, absorption peaks of NAD(P) and NAD(P)H, respectively. No blood metabolites were added to control eMVs. Error bars represent SD; $n = 3$. To clarify the plot, only statistical significance of the Mann–Whitney–Wilcoxon rank-sum test is included. $^*p < 0.05$, $^{**}p < 0.01$. In the Kruskall-Wallis test for young eMVs, significant differences were observed in control versus lactate and pyruvate ($p < 0.05$) and between glucose versus lactate ($p < 0.01$).
dilution of the samples, as well as the existence of carbohydrates in the molecule (the ribose rings), that makes MS analysis difficult, must also be considered.

In this work, we propose a model of organization of the metabolic routes in eMVs in accordance with our proteomic analysis (MS and WB) (see Figure 1). Although both young and senescent eMVs can synthesize reducing power, the latter have a stronger synthetic machinery. In fact, it seems that senescent eMVs redesign their metabolic machinery to optimize NADPH synthesis. This new metabolic reorganization has some interesting hallmarks. Mitochondrial activity is deeply affected in order to diminish its activity: (1) ADP/ATP translocases diminish or disappear: translocase 1 from 362 (young eMVs) to 0 (senescent eMVs) (protein score values), translocase 2 from 580 to 102, and translocase 3 from 549 to 0; (2) mitochondrial aminotransferases also diminish or disappear: ornithine aminotransferase from 55 to 0, aspartate aminotransferase from 520 to 251, and serine hydroxymethyltransferase from 339 to 122; (3) pyruvate dehydrogenase which contributes to transforming pyruvate into acetyl-CoA, a metabolite used in the tricarboxylic acid

Figure 4: eMVs observed with a multiphoton confocal microscope. (a) Young eMVs under control conditions; arrows indicate eMVs. The square delimited by a dotted line is a magnification of the two eMVs indicated by the two arrows. (b) Senescent eMVs after glycerol incubation. (c) Young eMVs after lactate incubation. (d) Senescent eMVs after pyruvate incubation. The different size of the eMVs in the image is due to the fact that the eMVs were floating in the buffer in different positions in the z-axis. eMVs were obtained after mixing four pools. Scale bar, 1 μm.

Figure 5: MS analysis of NADP⁺ (6.88 elution time) and NADPH (8.79 elution time) content in senescent eMVs. eMVs were obtained after mixing four pools. NADP⁺ MW: 742 D, NADPH MW: 744 D.
well as NAD(P)H dehydrogenase and aldehyde dehydrogenases are increased in senescent eMVs, as evidenced in Table 2; and (4) the TCA enzymes are diminished (see above paragraph), and malic enzyme and NAD kinase have not been detected. A serine-related folate-dependent NADPH production has been demonstrated in proliferating [43] and in cancer [44] cells; however, the enzymes of this route have not been detected in our study.

Under high oxidative conditions, the PPP consumes more glucose to compensate for the depleted GSH [45]; in fact, a high oxidative stress drives G6P to the PPP, generating NADPH for antioxidant defenses [46], and a mechanistic link between increased G6PD (number 10) activity, elevated NADPH, and improved antioxidant protection has been suggested [47]. An activation of the PPP has also been demonstrated in cancer cells, probably to produce more NADPH to combat oxidative stress [48]; indeed, the existence of PPP enzymes has been demonstrated in exosomes of ovarian cancer cells in proteomic analysis [37]. Human skin cells also activate the PPP in response to oxidative stress [49], and senescent fibroblasts show increased glycolysis and PPP to reduce ROS production, upregulation of pathways involved in redox homeostasis [50], and alterations in nicotinamide metabolism [51]. Moreover, another different metabolic possibility has been suggested for ROS scavenging; the enzyme biliverdin reductase has been involved in a ROS-scavenging mechanism in a subpopulation of epididymal fluid MVs, protecting spermatozoa against ROS released from dying cells [52].

Evidence that MVs are a heterogeneous population is continuously increasing [53]. This heterogeneity can be considered at least from two different points of view: structural (size) and functional (biochemical). In our functional analysis using multiphoton confocal microscopy, not all MVs emitted fluorescence after their stimulation. In fact, we think that only a part of the eMVs could act as ROS scavengers. We have just seen that to accomplish this function, it is necessary to reorganize the metabolic routes of the eMVs, and it is logical to assume that this drastic reorganization may not be useful for other functions supported by MVs; for example, for those MVs capable of ROS synthesis and involved in signaling processes [54–56].

eMVs, or at least a subpopulation of them, produce reducing power, but the enzymatic machinery involved in this process also needs to be fed. In this study, we have demonstrated that lactate, pyruvate, glucose, glycerol, and BCAA fuel this reducing power synthetic machinery. All these metabolites are present in blood plasma and, except glycerol that diffuses freely, need membrane transporters to cross the plasma membrane and get into the MVs. Lactic acid can also diffuse freely; however, in the blood, it is dissociated and present as lactate (ionized) that cannot pass through the plasma membrane. The use of these metabolites is different in young (only use lactate and pyruvate) and senescent eMVs (use all). Obviously, the higher reducing power synthesis capacity of senescent cells is in accordance with their wider metabolite availability. On the other hand, the use of some of these metabolites could represent another metabolic advantage; for example, the use of lactate may serve to regulate lactate concentration and to prevent lactic acidosis and redox regulation in plasma. We have not detected monocarboxylate transporters (lactate and pyruvate transporters), neutral amino acid transporters, or glucose transporters in our proteomic study; however, the fluorescence emission

---

**Figure 6:** A young (a) and a senescent (b) eMV. AOM: antioxidant machinery; PPP: pentose phosphate pathway; GNG: gluconeogenesis; ROS: reactive oxygen species; DH: dehydrogenases; BCAA: branched-chain amino acids. Note that the senescent eMV has larger enzymatic machineries, uses more metabolites to feed them, and also has a higher capacity for ROS scavenging.
after incubation of the eMVs with these metabolites implies the existence of a transport system. A low expression of these transporters could explain this result, but the fast (a few minutes) emission of fluorescence in eMVs after incubation with these metabolites suggests the contrary. The possibility that the membrane proteins, due to their hydrophobicity, are harder to detect in MS, indeed requiring thiourea to solubilize them, should be considered.

The contribution of ROS to aging has been widely documented, although the beneficial effects produced by ROS have led to a new interpretation of this traditional view [57–59]. An increase of ROS production has also been related with senescence, an experimental model widely used in aging studies [20, 24, 60] and also demonstrated in our previous work in senescent endothelial cells [27]. In accordance with the stronger capacity of ROS elimination demonstrated by senescent eMVs in our previous work, the present study demonstrates a strong increase of the machinery involved in NADPH synthesis in senescent eMVs. However, the stronger capacity of senescent endothelial cells and their MVs to eliminate ROS and the higher ROS production observed in senescence seems paradoxical. Their increased capacity for ROS scavenging might be an adaptive mechanism to the higher oxidative stress of senescent cells, and it could be considered a strategy used by senescent cells to promote cell survival. Unfortunately, this increased ROS scavenging is unable to compensate the higher levels of oxidative stress associated with senescence. On the other hand, eMVs can not only eliminate ROS but can also be effective in protecting against oxidative stress, suppressing NADPH oxidase and ROS production [32]. Finally, it should be considered that these results are obtained using the in vitro replicative senescent model in HUVEC; undoubtedly, this is a starting point that needs to be confirmed in in vivo aging models.

5. Conclusions

Our present and previous results demonstrate that eMVs can act as autonomous ROS scavengers: they use blood metabolites to synthesize NADPH that fuels their antioxidant machinery; moreover, senescent eMVs have a stronger ROS-scavenging capacity. Whether alterations in the ability of eMVs to regulate the oxidant/antioxidant balance can act as etiopathogenic mechanisms in diseases associated to a misbalance in oxidative stress is left out of this study but probably merits to be considered in order to use these MVs as diagnostic tools and/or therapeutic targets.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Guillermo Bodega, Matilde Alique, and Manuel R. Ramírez designed the study. Sergio Ciordia and María C. Mena carried out mass spectrometry analysis; Matilde Alique the Western blot analysis; Guillermo Bodega, Lourdes Bohórquez, Miriam Morán, and Luis Magro the functional analysis; and Guillermo Bodega and Elvira Arza the multiphoton confocal microscopy. Guillermo Bodega, Matilde Alique, Lilian Puebla, and Manuel R. Ramírez wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was funded by the Plan Nacional Proyectos de Investigación en Salud de Instituto de Salud Carlos III (ISCIII), EU FEDER Grant (PI14/00806). All proteomic analyses were performed at the Proteomics Facility of the Spanish National Center for Biotechnology (CNB-CSIC) (a member of ProteoRed, PRBB-ISCIII, financed via grant PT13/0001). The authors thank José María Arribas (Espectrometría de Masas y Análisis Elemental, Universidad de Alcalá) for NADPH analysis and Dr. Marcos Marvá (Departamento de Física y Matemáticas, Universidad de Alcalá) for statistical analysis.

References

[1] E. van der Pol, A. N. Böing, P. Harrison, A. Sturk, and R. Nieuwland, “Classification, functions, and clinical relevance of extracellular vesicles,” Pharmacological Reviews, vol. 64, no. 3, pp. 676–705, 2012.
[2] M. Colombo, G. Raposo, and C. Théry, “Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles,” Annual Review of Cell and Developmental Biology, vol. 30, no. 1, pp. 255–289, 2014.
[3] M. Yáñez-Mó, P. R. M. Siljander, Z. Andreu et al., “Biological properties of extracellular vesicles and their physiological functions,” Journal of Extracellular Vesicles, vol. 4, no. 1, article 27066, 2015.
[4] J.-D. Tissot, G. Canellini, O. Rubin et al., “Blood microvesicles: from proteomics to physiology,” Translational Proteomics, vol. 1, no. 1, pp. 38–52, 2013.
[5] S. M. Craige, S. Kant, and J. F. Keaney Jr., “Reactive oxygen species in endothelial function – from disease to adaptation,” Circulation Journal, vol. 79, no. 6, pp. 1145–1155, 2015.
[6] M. L. Liu and K. J. Williams, “Microvesicles: potential markers and mediators of endothelial dysfunction,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 2, pp. 121–127, 2012.
[7] A. Fleury, M. C. Martinez, and S. Le Lay, “Extracellular vesicles as therapeutic tools in cardiovascular diseases,” Frontiers in Immunology, vol. 5, p. 370, 2014.
[8] D. Vara and G. Pula, “Reactive oxygen species: physiological roles in the regulation of vascular cells,” Current Molecular Medicine, vol. 14, no. 9, pp. 1103–1125, 2014.
[9] Y. Zhou, H. Yan, M. Guo, J. Zhu, Q. Xiao, and L. Zhang, “Reactive oxygen species in vascular formation and development,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 374963, 14 pages, 2013.
[10] M. El Assar, J. Angulo, S. Vallejo, C. Peiró, C. F. Sánchez-Ferrer, and L. Rodríguez-Mañas, “Mechanisms involved in the aging-induced vascular dysfunction,” Frontiers in Physiology, vol. 3, p. 132, 2012.
[11] M. El Assar, J. Angulo, and L. Rodríguez-Mañas, “Oxidative stress and vascular inflammation in aging,” Free Radical Biology & Medicine, vol. 65, pp. 380–401, 2013.
[12] R. Brandes, I. Fleming, and R. Busse, “Endothelial aging,” Cardiovascular Research, vol. 66, no. 2, pp. 286–294, 2005.

[13] Y. Mikked, A. Daiber, and S. Steven, “Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 15918–15953, 2015.

[14] A. A. Puca, A. Carrizzo, F. Villa et al., “Vascular ageing: the role of oxidative stress,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 3, pp. 556–559, 2013.

[15] N. S. Dhall, R. M. Temsah, and T. Netticadan, “Role of oxidative stress in cardiovascular diseases,” Journal of Hypertension, vol. 18, no. 6, pp. 655–673, 2000.

[16] H. Li, S. Horke, and U. Förstermann, “Oxidative stress in vascular disease and its pharmacological prevention,” Trends in Pharmacological Sciences, vol. 34, no. 6, pp. 313–319, 2013.

[17] N. R. Madamanchi, A. Vendrov, and M. S. Runge, “Oxidative stress and vascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 29–38, 2005.

[18] D. J. Kurz, S. Decary, Y. Hong, E. Trivier, A. Akhmedov, and J. D. Erusalimsky, “Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells,” Journal of Cell Science, vol. 117, no. 11, pp. 2417–2426, 2004.

[19] E. Schulz, E. Anter, and J. F. Keaney Jr., “Oxidative stress, antioxidants, and endothelial function,” Current Medicinal Chemistry, vol. 11, no. 9, pp. 1093–1104, 2004.

[20] J. D. Erusalimsky and C. Skene, “Mechanisms of endothelial senescence,” Experimental Physiology, vol. 94, no. 3, pp. 299–304, 2009.

[21] V. Victor, N. Apostolova, R. Herance, A. Hernandez-Mijares, and M. Rocha, “Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy,” Current Medicinal Chemistry, vol. 16, no. 35, pp. 4654–4667, 2009.

[22] D. R. Seals, K. L. Jablonski, and A. J. Donato, “Aging and vascular endothelial function in humans,” Clinical Science, vol. 120, no. 9, pp. 357–375, 2011.

[23] A. J. Donato, R. G. Morgan, A. E. Walker, and L. A. Lesniewski, “Cellular and molecular biology of aging endothelial cells,” Journal of Molecular and Cellular Cardiology, vol. 89, Part B, pp. 122–135, 2015.

[24] R. Liu, H. Liu, Y. Ha, R. G. Tilton, and W. Zhang, “Oxidative stress induces endothelial cell senescence via downregulation of Sirt6,” BioMed Research International, vol. 2014, Article ID 902842, 13 pages, 2014.

[25] W. Ying, “NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences,” Antioxidants & Redox Signaling, vol. 10, no. 2, pp. 179–206, 2008.

[26] L. Agledal, M. Niere, and M. Ziegler, “The phosphate makes a difference: cellular functions of NADP+,” Redox Report, vol. 15, no. 1, pp. 2–10, 2010.

[27] G. Bodega, M. Alique, L. Bohórquez, S. Ciordia, M. C. Mena, and M. R. Ramírez, “The antioxidant machinery of young and senescent human umbilical vein endothelial cells and their microvesicles,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 7094781, 12 pages, 2017.

[28] J. Carracedo, P. Buendia, A. Merino et al., “Cellular senescence determines endothelial cell damage induced by uremia,” Experimental Gerontology, vol. 48, no. 8, pp. 766–773, 2013.

[29] K. Ortmayr, Quantitative Analysis of NADP+ and NADPH in Yeast, [M.S. thesis], University of Natural Resources and Life Science, Vienna, Austria, 2013.

[30] A. Shevchenko, M. Wilm, O. Vorm, and M. Mann, “Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels,” Analytical Chemistry, vol. 68, no. 5, pp. 850–858, 1996.

[31] R. Soleti, E. Lauret, R. Andriantsitohaina, and M. Carmen Martínez, “Internalization and induction of antioxidant messages by microvesicles contribute to the antiapoptotic effects on human endothelial cells,” Free Radical Biology & Medicine, vol. 53, no. 11, pp. 2159–2170, 2012.

[32] A. M. Mahmoud, F. L. Wilkinson, E. M. McCarthy et al., “Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress,” The FASEB Journal, vol. 31, no. 10, pp. 4636–4648, 2017.

[33] M. Jin, G. Drwal, T. Bourgeois, J. Saltz, and H. M. Wu, “Distinct proteome features of plasma microparticles,” Proteomics, vol. 5, no. 7, pp. 1940–1952, 2005.

[34] D. B. Peterson, T. Sander, S. Kaul et al., “Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles,” Proteomics, vol. 8, no. 12, pp. 2430–2446, 2008.

[35] D. Povero, A. Eguchi, H. Li et al., “Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease,” PLoS One, vol. 9, no. 12, article e113651, 2014.

[36] K. Little, D. Smalley, N. Harthun, and K. Ley, “The plasma microparticle proteome,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 8, pp. 845–856, 2010.

[37] H. Yi, X. Zheng, J. Song, R. Shen, Y. Su, and D. Lin, “Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 12, pp. 15719–15728, 2015.

[38] T. S. Blacker, Z. F. Mann, J. E. Gale et al., “Separating NADH and NADPH fluorescence in live cells and tissues using FLIM,” Nature Communications, vol. 5, p. 3936, 2014.

[39] T. S. Blacker and M. R. Duchen, “Investigating mitochondrial redox state using NADH and NADPH autofluorescence,” Free Radical Biology & Medicine, vol. 100, pp. 53–65, 2016.

[40] J. T. Wu, L. H. Wu, and J. A. Knight, “Stability of NADPH: effect of various factors on the kinetics of degradation,” Clinical Chemistry, vol. 32, no. 2, pp. 314–319, 1986.

[41] A. Stincone, A. Prigione, T. Cramer et al., “The return of metabolism: biochemistry and physiology of the pentose phosphate pathway,” Biological Reviews of the Cambridge Philosophical Society, vol. 90, no. 3, pp. 927–963, 2015.

[42] N. Pollak, C. Dölle, and M. Ziegler, “The power to reduce: pyridine nucleotides – small molecules with a multitude of functions,” The Biochemical Journal, vol. 402, no. 2, pp. 205–218, 2007.

[43] J. Fan, J. Ye, J. J. Kamphorst, T. Shlomi, C. B. Thompson, and J. D. Rabinowitz, “Quantitative flux analysis reveals folate-dependent NADPH production,” Nature, vol. 510, no. 7504, pp. 298–302, 2014.

[44] A. Antonov, M. Agostini, M. Morello, M. Minieri, G. Melino, and I. Amelio, “Bioinformatics analysis of the serine and glycine pathway in cancer cells,” Oncotarget, vol. 5, no. 22, pp. 11004–11013, 2014.
[45] M. F. McMullin, “The molecular basis of disorders of the red cell membrane,” Journal of Clinical Pathology, vol. 52, no. 4, pp. 245–248, 1999.

[46] R. B. Hamanaka and N. S. Chandel, “Warburg effect and redox balance,” Science, vol. 334, no. 6060, pp. 1219-1220, 2011.

[47] S. Nóbrega-Pereira, P. J. Fernández-Marcos, T. Brioche et al., “G6PD protects from oxidative damage and improves health-span in mice,” Nature Communications, vol. 7, article 10894, 2016.

[48] K. C. Patra and N. Hay, “The pentose phosphate pathway and cancer,” Trends in Biochemical Sciences, vol. 39, no. 8, pp. 347–354, 2014.

[49] A. Kuehne, H. Emmert, J. Soehle et al., “Acute activation of oxidative pentose phosphate pathway as first-line response to oxidative stress in human skin cells,” Molecular Cell, vol. 59, no. 3, pp. 359–371, 2015.

[50] E. L. James, R. D. Michalek, G. N. Pitiyage et al., “Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease,” Journal of Proteome Research, vol. 14, no. 4, pp. 1854–1871, 2015.

[51] E. L. James, J. A. E. Lane, R. D. Michalek, E. D. Karoly, and E. K. Parkinson, “Replicatively senescent human fibroblasts reveal a distinct intracellular metabolic profile with alterations in NAD+ and nicotinamide metabolism,” Scientific Reports, vol. 6, no. 1, article 38489, 2016.

[52] R. Sullivan, “Epididymosomes: a heterogeneous population of microvesicles with multiple functions in sperm maturation and storage,” Asian Journal of Andrology, vol. 17, no. 5, pp. 726–729, 2015.

[53] B. Giebel, “On the function and heterogeneity of extracellular vesicles,” Annals of Translational Medicine, vol. 5, no. 6, p. 150, 2017.

[54] M. C. Larson, C. A. Hillery, and N. Hogg, “Circulating membrane-derived microvesicles in redox biology,” Free Radical Biology & Medicine, vol. 73, pp. 214–228, 2014.

[55] D. Burger, M. Turner, M. N. Munkonda, and R. M. Touyz, “Endothelial microparticle-derived reactive oxygen species: role in endothelial signaling and vascular function,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5047954, 10 pages, 2016.

[56] Q. Zhang, M. Shang, M. Zhang et al., “Microvesicles derived from hypoxia/reoxygenation-treated human umbilical vein endothelial cells promote apoptosis and oxidative stress in H9c2 cardiomyocytes,” BMC Cell Biology, vol. 17, no. 1, p. 25, 2016.

[57] S. I. Liochev, “Reactive oxygen species and the free radical theory of aging,” Free Radical Biology & Medicine, vol. 60, pp. 1–4, 2013.

[58] J. Viña, C. Borras, K. M. Abdelaziz, R. García-Valles, and M. C. Gomez-Cabrera, “The free radical theory of aging revisited: the cell signaling disruption theory of aging,” Antioxidants & Redox Signaling, vol. 19, no. 8, pp. 779–787, 2013.

[59] A. B. Salmon, A. Richardson, and V. I. Pérez, “Update on the oxidative stress theory of aging: does oxidative stress play a role in aging or healthy aging?,” Free Radical Biology & Medicine, vol. 48, no. 5, pp. 642–655, 2010.

[60] H. Unterluggauer, B. Hampel, W. Zwerschke, and P. Jansen-Dürr, “Senescence-associated cell death of human endothelial cells: the role of oxidative stress,” Experimental Gerontology, vol. 38, no. 10, pp. 1149–1160, 2003.